Shots:

• The NMPA has approved an IND application for P-Ib MATCH, dose-escalation study to evaluate the safety of ATG-008 + ATG-010 in patients with r/r DLBCL. The study will be conducted at ten centers across China, including its primary trial center at Sun Yat-Sen University Cancer Center
• The 1EPs of the study include MTD and RP2D of ATG-008 + ATG-010 & 2EPs is lymphoma response as assessed according to the modified Lugano response criteria (Cheson 2014)
• In preclinical studies of the DoHH-2 cell line & DoHH2 CDX mice models, ATG-008 + ATG-010 showed a potent synergistic antitumor activity both in vivo and in vitro & will investigate the synergistic effect of the combination in DLBCL

/ article | Ref: PR Newswire | Image: Antengene